A novel study by Canadian physicians reported that the BioSTAR biodegradable implant achieved comparable closure rates to the Amplatzer Septal Occluder in children with atrial septal defect. A novel ...

May 31, 2007 (Seattle, WA) - The pivotal trial of a new device approved for the percutaneous closure of atrial septal defects (ASD)--the HELEX septal occluder (WL Gore and Associates, Flagstaff, ...

NEW YORK - March 12, 2019-The Cardiovascular Research Foundation (CRF) is pleased to announce that the latest issue of Structural Heart: The Journal of the Heart Team features original research ...

LONDON--(BUSINESS WIRE)--The report, heart defect closure devices market 2019-2023, has been added to Technavio's catalog. It provides a comprehensive analysis of the market, including its global and ...

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "US Market for Heart Defect Closure Devices - 2016 (Forecasted to 2022) - MedCore" report to their offering. As of ...

TCT 195: Percutaneous Patent Foramen Ovale Closure for Migraine with the Amplatzer PFO Occluder: A Pooled Analysis of Individual Participant Data from the Randomized Trials Receive the the latest news ...

The Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), Thiruvananthapuram, an institute of national importance, has developed a nickel-titanium alloy based occlusion device ...

Expert Rev Cardiovasc Ther. 2007;5(6):1135-1146. Diagnosing a secundum ASD is more often than not incidental because the defect normally causes symptoms late in adult life. Echocardiography and MRI ...

An atrial septal defect is the persistence of a hole (the foramen ovale) in the wall (septum) between the right atrium and left atrium of the heart. The foramen ovale usually closes spontaneously ...

An atrial septal defect of the secundum type is relatively common and occurs from failure of the septum secundum to develop. This results in a communication between the left and right atrium directly ...